RS3PE Presenting in a Unilateral Pattern: Case Report and Review of the Literature

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 6, 2009, Pages 428-433

  Keenan, Robert T ^a   Hamalian, Gareen M ^a   Pillinger, Michael H ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

asymmetrical; hemiplegia; neurological injury; pitting edema; RS3PE; unilateral

Indexed keywords

CEFALEXIN; IBUPROFEN; INDOMETACIN; METHYLPREDNISOLONE; NAPROXEN; PARACETAMOL; PREDNISOLONE; PREDNISONE; SULTAMICILLIN; GLUCOCORTICOID;

AGED; ARTHRITIS; ARTICLE; CASE REPORT; CELLULITIS; CEREBROVASCULAR ACCIDENT; DOPPLER ECHOGRAPHY; DRUG DOSE REDUCTION; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HAND; HEMIPARESIS; HUMAN; LABORATORY TEST; LOW DRUG DOSE; MALE; METACARPOPHALANGEAL JOINT; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REMITTING SERONEGATIVE SYMMETRICAL SYNOVITIS WITH PITTING EDEMA; SWELLING; WRIST; HAND JOINT; PARESIS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SYNOVITIS; TREATMENT OUTCOME;

AGED; ARTHRITIS; EDEMA; GLUCOCORTICOIDS; HAND JOINTS; HUMANS; MALE; METACARPOPHALANGEAL JOINT; PARESIS; PREDNISONE; SYNOVITIS; TREATMENT OUTCOME; WRIST JOINT;

EID: 67349113932     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.03.008     Document Type: Article

References (61)

1. Olivieri I., Salvarani C., and Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol 18 4 Suppl 20 (2000) S53-S55
2. Roldan M.R., Martinez F., Roman J., and Torres A. Non-Hodgkin's lymphoma: initial manifestation. Ann Rheum Dis 52 1 (1993) 85-86
3. Sayarlioglu M., Bayram I., Sayarlioglu H., and Erkoc R. Remitting seronegative symmetrical synovitis with pitting edema syndrome associated with non-Hodgkin's lymphoma: a case report. Clin Rheumatol 23 2 (2004) 188-189
4. Cantini F., Salvarani C., and Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol 17 6 (1999) 741-744
5. Olivo D., and Mattace R. Concurrence of benign edematous polysynovitis in the elderly (RS3PE syndrome) and endometrial adenocarcinoma. Scand J Rheumatol 26 1 (1997) 67-68
6. Paira S., Graf C., Roverano S., and Rossini J. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol 21 2 (2002) 146-149
7. Paira S., Caliani L., and Luraquiz N. Distal extremity swelling with pitting oedema in rheumatoid arthritis. Clin Rheumatol 20 1 (2001) 76-79
8. Fietta P., and Manganelli P. Remitting seronegative symmetrical synovitis with pitting edema and primary Sjogren's syndrome. Clin Exp Rheumatol 18 2 (2000) 269-270
9. Fietta P, Manganelli P. Sjogren's syndrome presenting as remitting seronegative symmetric synovitis with pitting edema (RS3PE): comment of the article by Choi et al. J Korean Med Sci 921;18(6):921.
10. Manganelli P., Delsante G., Bianchi G., Fietta P., and Quaini F. Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis. Clin Rheumatol 20 2 (2001) 132-135
11. Olivieri I., Salvarani C., and Cantini F. Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?. J Rheumatol 24 2 (1997) 249-252
12. Olivieri I., Salvarani C., Cantini F., Barozzi L., Macchioni L., and Pavlica P. Distal extremity swelling with pitting edema in polymyalgia rheumatica: a case studied with MRI. Clin Exp Rheumatol 15 6 (1997) 710-711
13. Olivieri I., Padula A., Pierro A., Favaro L., Oranges G.S., and Ferri S. Late onset undifferentiated seronegative spondyloarthropathy. J Rheumatol 22 5 (1995) 899-903
14. Dubost J.J., and Sauvezie B. Late onset peripheral spondyloarthropathy. J Rheumatol 16 9 (1989) 1214-1217
15. Schaeverbeke T., Fatout E., Marce S., Vernhes J.P., Hallé O., Antoine J.F., et al. Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome?. Ann Rheum Dis 54 8 (1995) 681-684
16. Olive A., del Blanco J., Pons M., Vaquero M., Tena X., and The Catalan Group for the Study of RS3PE. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol 24 2 (1997) 333-336
17. Pariser K.M., and Canoso J.J. Remitting, seronegative (A) symmetrical synovitis with pitting edema-two cases of RS3PE syndrome. J Rheumatol 18 8 (1991) 1260-1262
18. Olivieri I., Padula A., Favaro L., Oranges G.S., and Ferri S. RS3PE syndrome with unilateral involvement. J Rheumatol 21 2 (1994) 372
19. Pierro A., Favaro L., Olivieri I., Amoresano C., and Ferri S. Another case of RS3PE with unilateral involvement. Reumatismo 47 (1995) 25-26
20. Segerer S., Dietz-Laukemann P., and Schattenkirchner M. RS3PE-syndrome. Z Rheumatol 58 1 (1999) 35-38
21. McCarty D.J., O'Duffy J.D., Pearson L., and Hunter J.B. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254 19 (1985) 2763-2767
22. Russell E.B. Remitting seronegative symmetrical synovitis with pitting edema syndrome: follow-up for neoplasia. J Rheumatol 32 9 (2005) 1760-1761
23. Koeger A.C., Karmochkine M., and Chaibi P. RS3PE syndrome associated with advanced ankylosing spondylitis. J Rheumatol 22 2 (1995) 375-376
24. Pease C., and Bhakta B. RS3PE syndrome. The relation with HLA B7. Ann Rheum Dis 59 3 (2000) 239-240
25. Mouly S., Berenbaum F., and Kaplan G. Remitting seronegative symmetrical synovitis with pitting edema following intravesical bacillus Calmette-Guerin instillation. J Rheumatol 28 7 (2001) 1699-1701
26. Perandones C.E., Colmegna I., and Arana R.M. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol 32 2 (2005) 389-390
27. Dolan AL. Asymmetric rheumatoid vasculitis in a hemiplegic patient. Ann Rheum Dis 532;54(6):532.
28. Thompson M., and Bywaters E.G. Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis 21 (1962) 370-377
29. Sethi S., and Sequeira W. Sparing effect of hemiplegia on scleroderma. Ann Rheum Dis 49 12 (1990) 999-1000
30. Bland J.H., and Eddy W.M. Hemiplegia and rheumatoid hemiarthritis. Arthritis Rheum 11 1 (1968) 72-80
31. Yaghmai I., Rooholamini S.M., and Faunce H.F. Unilateral rheumatoid arthritis: protective effect of neurologic deficits. AJR Am J Roentgenol 128 2 (1977) 299-301
32. Kamermann J.S. Protective effect of traumatic lesions on rheumatoid arthritis. Ann Rheum Dis 25 4 (1966) 361-363
33. Glynn J.J., and Clayton M.L. Sparing effect of hemiplegia on tophaceous gout. Ann Rheum Dis 35 6 (1976) 534-535
34. Keyszer G., Langer T., Kornhuber M., Taute B., and Horneff G. Neurovascular mechanisms as a possible cause of remission of rheumatoid arthritis in hemiparetic limbs. Ann Rheum Dis 63 10 (2004) 1349-1351
35. Levine J.D., Collier D.H., Basbaum A.I., Moskowitz M.A., and Helms C.A. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol 12 3 (1985) 406-411
36. Courtright L.J., and Kuzell W.C. Sparing effect of neurological deficit and trauma on the course of adjuvant arthritis in the rat. Ann Rheum Dis 24 4 (1965) 360-368
37. Decaris E., Guingamp C., Chat M., et al. Evidence for neurogenic transmission inducing degenerative cartilage damage distant from local inflammation. Arthritis Rheum 42 9 (1999) 1951-1960
38. Kidd B.L., Mapp P.I., Blake D.R., Gibson S.J., and Polak J.M. Neurogenic influences in arthritis. Ann Rheum Dis 49 8 (1990) 649-652
39. Levine J.D., Goetzl E.J., and Basbaum A.I. Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides. Rheum Dis Clin North Am 13 2 (1987) 369-383
40. Lotz M., Carson D.A., and Vaughan J.H. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235 4791 (1987) 893-895
41. Perianin A., Snyderman R., and Malfroy B. Substance P primes human neutrophil activation: a mechanism for neurological regulation of inflammation. Biochem Biophys Res Commun 161 2 (1989) 520-524
42. Haines K.A., Kolasinski S.L., Cronstein B.N., Reibman J., Gold L.I., and Weissmann G. Chemoattraction of neutrophils by substance P and transforming growth factor-beta 1 is inadequately explained by current models of lipid remodeling. J Immunol 151 3 (1993) 1491-1499
43. Kolasinski S.L., Haines K.A., Siegel E.L., Cronstein B.N., and Abramson S.B. Neuropeptides and inflammation. A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum 35 4 (1992) 369-375
44. Kulka M., Sheen C.H., Tancowny B.P., Grammer L.C., and Schleimer R.P. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123 3 (2008) 398-410 Oct. 6; [Epub ahead of print]
45. Cuesta M.C., Quintero L., Pons H., and Suarez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem Int 40 4 (2002) 301-306
46. Braun A., Wiebe P., Pfeufer A., Gessner R., and Renz H. Differential modulation of human immunoglobulin isotype production by the neuropeptides substance P, NKA and NKB. J Neuroimmunol 97 1-2 (1999) 43-50
47. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16 6 (2002) 622-653
48. Black P.H. Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain. Antimicrob Agents Chemother 38 1 (1994) 7-12
49. Kuraishi Y., Hirota N., Sato Y., Hanashima N., Takagi H., and Satoh M. Stimulus specificity of peripherally evoked substance P release from the rabbit dorsal horn in situ. Neuroscience 30 1 (1989) 241-250
50. Rosenkranz M.A. Substance P at the nexus of mind and body in chronic inflammation and affective disorders. Psychol Bull 133 6 (2007) 1007-1037
51. Lee C.G., Link H., Baluk P., Homer R.J., Chapoval S., Bhandari V., et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10 10 (2004) 1095-1103
52. Tammela T., Enholm B., Alitalo K., and Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 65 3 (2005) 550-563
53. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 6 (2003) 669-676
54. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik J.P., Cylwik B., Skowronski J., et al. Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61 9 (2002) 804-809
55. Arima K., Origuchi T., Tamai M., Iwanaga N., Izumi Y., Huang M., et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 64 11 (2005) 1653-1655
56. Brockington A., Wharton S.B., Fernando M., Gelsthorpe C.H., Baxter L., Ince P.G., et al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65 1 (2006) 26-36
57. Tham E., Gielen A.W., Khademi M., Martin C., and Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand J Immunol 64 6 (2006) 609-622
58. Cronstein B.N. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 65 Suppl 1 (2007) S11-S15
59. Biber K., Pinto-Duarte A., Wittendorp M.C., Dolga A.M., Fernandes C.C., Von Frijtag Drabbe Künzel J., et al. Interleukin-6 upregulates neuronal adenosine A(1) receptors: implications for neuromodulation and neuroprotection. Neuropsychopharmacology (2007) Nov. 7; [Epub ahead of print]
60. Bours M.J., Swennen E.L., Di Virgilio F., Cronstein B.N., and Dagnelie P.C. Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther 112 2 (2006) 358-404
61. Cohen T., Nahari D., Cerem L.W., Neufeld G., and Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271 2 (1996) 736-741